BioInvent International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, sales was SEK 56.14 million compared to SEK 305.49 million a year ago. Net loss was SEK 233.15 million compared to net income of SEK 35.83 million a year ago. Basic loss per share from continuing operations was SEK 3.55 compared to basic earnings per share from continuing operations of SEK 0.59 a year ago. Diluted loss per share from continuing operations was SEK 3.55 compared to diluted earnings per share from continuing operations of SEK 0.59 a year ago.